Akura Raises Financing for Thrombectomy System and Quantification Software

December 1, 2025—Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced it has secured a $53 million first close in Series C financing.

The company advised that the funds will be used to support development activities for the Katana thrombectomy system and the NavIQ quantification software; completion of enrollment in the QUADRA-PE clinical trial; and regulatory submissions.

The round was led by Qatar Investment Authority with participation by current investors. Part of the funds will be used to set up a joint venture in Qatar, stated the company.

According to Akura Medical, the investigational Katana thrombectomy system is designed to remove diverse clot types, optimize catheter delivery, and provide supplementary intraoperative feedback. The system leverages high-velocity saline jets to break up clots independent of morphology and prevent catheter clogging for procedural efficiency. The system also incorporates sensors that provide real-time pulmonary artery pressure data to provide insights into procedure progress.

The NavIQ quantification software is designed to convert a CT angiogram into a three-dimensional model of the pulmonary vasculature. The model is intended for use in anatomical visualization of the arteries and clots to allow for preprocedural planning. Additionally, NavIQ is designed to provide clot characterization data to assist physicians with treatment prioritization, stated Akura Medical.